This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. AIDS related: High-dose myeloablative therapy, followed by hematopoietic stem cell transplantation (HSCT), is an increasingly utilized treatment for many malignancies. However, patient survival may be limited by substantial treatment-related toxicities. Among the most severe of these toxicities is renal dysfunction, which occurs frequently in the period immediately following HSCT. Renal insufficiency is also a major cause of morbidity in the first year post-transplant and beyond. Our objectives are to characterize the epidemiology and pathophysiology of both acute and chronic renal insufficiency after hematopoietic stem cell transplantation (HSCT); to identify early markers of renal injury; and, if possible, to devise strategies to lessen the burden of kidney disease in this population. To do this, we will utilize the massive patient database at the Fred Hutchinson Cancer Research Center (FHCRC). Over, 10,000 patients have undergone marrow or peripheral blood stem cell transplantation at this institution. Each year approximately 400 new HSCTs are performed. The Long-Term Follow-Up Unit (LTFU) at the Center has a well-developed tracking system and only a small percentage of long-term survivors have been lost to follow-up.
Showing the most recent 10 out of 563 publications
